URGN
UroGen Pharma Ltd.
URGN
(2.8)11,19 USD
-40.3% ROA
388.24% ROE
-4.25x PER
552.115.851,00 USD
325.29% DER
0% Yield
-133.61% NPM
UroGen Pharma Ltd. Stock Analysis
UroGen Pharma Ltd. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
ROE
ROE surpassing expectations (106.56%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect. |
|
| 2 |
PBV
The stock's low PBV ratio (-2.11x) suggests it's undervalued, making it an attractive opportunity for investors. |
|
| 3 |
DER
The stock has a minimal amount of debt (-72%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 4 |
Revenue Growth
Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity. |
|
| 5 |
Net Profit Growth
This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity. |
|
| 6 |
Assets Growth
With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity |
|
| 7 |
Graham Number
The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity. |
|
| 8 |
ROA
The stock's ROA (-113.7%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns. |
|
| 9 |
Dividend Growth
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns. |
|
| 10 |
Dividend
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments. |
|
| 11 |
Buffet Intrinsic Value
The company's stock shows signs of being overvalued (-8) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value. |
UroGen Pharma Ltd. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
UroGen Pharma Ltd. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2013 | 0 | |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 17.530.000 | 100% |
| 2017 | 8.158.000 | -114.88% |
| 2018 | 1.128.000 | -623.23% |
| 2019 | 18.000 | -6166.67% |
| 2020 | 11.799.000 | 99.85% |
| 2021 | 48.042.000 | 75.44% |
| 2022 | 64.357.000 | 25.35% |
| 2023 | 83.408.000 | 22.84% |
| 2023 | 82.713.000 | -0.84% |
| 2024 | 87.392.000 | 5.35% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2013 | 2.334.000 | |
| 2014 | 4.008.000 | 41.77% |
| 2015 | 10.515.000 | 61.88% |
| 2016 | 10.287.000 | -2.22% |
| 2017 | 18.697.000 | 44.98% |
| 2018 | 36.934.000 | 49.38% |
| 2019 | 49.297.000 | 25.08% |
| 2020 | 47.310.000 | -4.2% |
| 2021 | 47.642.000 | 0.7% |
| 2022 | 52.906.000 | 9.95% |
| 2023 | 40.920.000 | -29.29% |
| 2023 | 45.614.000 | 10.29% |
| 2024 | 61.608.000 | 25.96% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2013 | 1.055.000 | |
| 2014 | 890.000 | -18.54% |
| 2015 | 1.895.000 | 53.03% |
| 2016 | 6.417.000 | 70.47% |
| 2017 | 8.811.000 | 27.17% |
| 2018 | 39.571.000 | 77.73% |
| 2019 | 60.199.000 | 34.27% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2013 | -3.371.000 | |
| 2014 | -4.339.000 | 22.31% |
| 2015 | -12.297.000 | 64.71% |
| 2016 | 1.011.000 | 1316.32% |
| 2017 | -19.950.000 | 105.07% |
| 2018 | -77.180.000 | 74.15% |
| 2019 | -108.154.000 | 28.64% |
| 2020 | -126.739.000 | 14.66% |
| 2021 | -75.001.000 | -68.98% |
| 2022 | -78.031.000 | 3.88% |
| 2023 | -48.716.000 | -60.18% |
| 2023 | -63.831.000 | 23.68% |
| 2024 | -102.304.000 | 37.61% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2013 | 0 | |
| 2014 | 0 | 0% |
| 2015 | -113.000 | 100% |
| 2016 | 17.502.000 | 100.65% |
| 2017 | 7.558.000 | -131.57% |
| 2018 | -675.000 | 1219.7% |
| 2019 | 18.000 | 3850% |
| 2020 | 10.790.000 | 99.83% |
| 2021 | 42.885.000 | 74.84% |
| 2022 | 56.703.000 | 24.37% |
| 2023 | 73.940.000 | 23.31% |
| 2023 | 73.352.000 | -0.8% |
| 2024 | 78.476.000 | 6.53% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2013 | -3.306.000 | |
| 2014 | -4.557.000 | 27.45% |
| 2015 | -12.689.000 | 64.09% |
| 2016 | -1.941.000 | -553.74% |
| 2017 | -20.000.000 | 90.3% |
| 2018 | -75.657.000 | 73.56% |
| 2019 | -100.530.000 | 24.74% |
| 2020 | -128.484.000 | 21.76% |
| 2021 | -110.820.000 | -15.94% |
| 2022 | -109.163.000 | -1.52% |
| 2023 | -87.516.000 | -24.73% |
| 2023 | -102.244.000 | 14.4% |
| 2024 | -133.612.000 | 23.48% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2013 | -2 | |
| 2014 | -2 | 0% |
| 2015 | -1 | 0% |
| 2016 | 0 | 0% |
| 2017 | -2 | 100% |
| 2018 | -5 | 50% |
| 2019 | -5 | 0% |
| 2020 | -6 | 20% |
| 2021 | -5 | -25% |
| 2022 | -5 | 0% |
| 2023 | -3 | -100% |
| 2023 | -4 | 33.33% |
| 2024 | -4 | 0% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2013 | -2.614.000 | |
| 2014 | -4.141.000 | 36.88% |
| 2015 | -7.476.000 | 44.61% |
| 2016 | 3.494.000 | 313.97% |
| 2017 | -9.842.000 | 135.5% |
| 2018 | -37.894.000 | 74.03% |
| 2019 | -71.342.000 | 46.88% |
| 2020 | -107.101.000 | 33.39% |
| 2021 | -85.644.000 | -25.05% |
| 2022 | -87.813.000 | 2.47% |
| 2023 | -76.570.000 | -14.68% |
| 2023 | -17.399.000 | -340.08% |
| 2024 | -31.735.000 | 45.17% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2013 | -2.557.000 | |
| 2014 | -4.117.000 | 37.89% |
| 2015 | -7.175.000 | 42.62% |
| 2016 | 4.189.000 | 271.28% |
| 2017 | -9.571.000 | 143.77% |
| 2018 | -37.334.000 | 74.36% |
| 2019 | -71.017.000 | 47.43% |
| 2020 | -105.886.000 | 32.93% |
| 2021 | -84.892.000 | -24.73% |
| 2022 | -87.559.000 | 3.05% |
| 2023 | -76.376.000 | -14.64% |
| 2023 | -17.299.000 | -341.51% |
| 2024 | -31.735.000 | 45.49% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2013 | 57.000 | |
| 2014 | 24.000 | -137.5% |
| 2015 | 301.000 | 92.03% |
| 2016 | 695.000 | 56.69% |
| 2017 | 271.000 | -156.46% |
| 2018 | 560.000 | 51.61% |
| 2019 | 325.000 | -72.31% |
| 2020 | 1.215.000 | 73.25% |
| 2021 | 752.000 | -61.57% |
| 2022 | 254.000 | -196.06% |
| 2023 | 194.000 | -30.93% |
| 2023 | 100.000 | -94% |
| 2024 | 0 | 0% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2013 | 2.741.000 | |
| 2014 | 3.468.000 | 20.96% |
| 2015 | 16.281.000 | 78.7% |
| 2016 | 16.307.000 | 0.16% |
| 2017 | 68.515.000 | 76.2% |
| 2018 | 90.094.000 | 23.95% |
| 2019 | 180.302.000 | 50.03% |
| 2020 | 96.355.000 | -87.12% |
| 2021 | 8.413.000 | -1045.31% |
| 2022 | -88.741.000 | 109.48% |
| 2023 | -65.212.000 | -36.08% |
| 2023 | -41.993.000 | -55.29% |
| 2024 | 30.314.000 | 238.53% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2013 | 3.225.000 | |
| 2014 | 4.359.000 | 26.02% |
| 2015 | 19.390.000 | 77.52% |
| 2016 | 23.056.000 | 15.9% |
| 2017 | 75.550.000 | 69.48% |
| 2018 | 103.559.000 | 27.05% |
| 2019 | 202.388.000 | 48.83% |
| 2020 | 122.005.000 | -65.89% |
| 2021 | 119.746.000 | -1.89% |
| 2022 | 136.239.000 | 12.11% |
| 2023 | 178.311.000 | 23.59% |
| 2023 | 193.633.000 | 7.91% |
| 2024 | 281.849.000 | 31.3% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2013 | 484.000 | |
| 2014 | 891.000 | 45.68% |
| 2015 | 3.109.000 | 71.34% |
| 2016 | 6.749.000 | 53.93% |
| 2017 | 7.035.000 | 4.07% |
| 2018 | 13.465.000 | 47.75% |
| 2019 | 22.086.000 | 39.03% |
| 2020 | 25.650.000 | 13.89% |
| 2021 | 111.333.000 | 76.96% |
| 2022 | 224.980.000 | 50.51% |
| 2023 | 243.523.000 | 7.61% |
| 2023 | 235.626.000 | -3.35% |
| 2024 | 251.535.000 | 6.32% |
UroGen Pharma Ltd. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 2.31
- Net Income per Share
- -3.08
- Price to Earning Ratio
- -4.25x
- Price To Sales Ratio
- 6.49x
- POCF Ratio
- -5.86
- PFCF Ratio
- -6.69
- Price to Book Ratio
- 15.92
- EV to Sales
- 5.06
- EV Over EBITDA
- -5.57
- EV to Operating CashFlow
- -5.23
- EV to FreeCashFlow
- -5.21
- Earnings Yield
- -0.24
- FreeCashFlow Yield
- -0.15
- Market Cap
- 0,55 Bil.
- Enterprise Value
- 0,43 Bil.
- Graham Number
- 7.56
- Graham NetNet
- 0.19
Income Statement Metrics
- Net Income per Share
- -3.08
- Income Quality
- 0.79
- ROE
- 3.88
- Return On Assets
- -0.4
- Return On Capital Employed
- -0.32
- Net Income per EBT
- 1.04
- EBT Per Ebit
- 1.38
- Ebit per Revenue
- -0.94
- Effective Tax Rate
- -0.04
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 0.62
- Stock Based Compensation to Revenue
- 0.12
- Gross Profit Margin
- 0.9
- Operating Profit Margin
- -0.94
- Pretax Profit Margin
- -1.29
- Net Profit Margin
- -1.34
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -2.24
- Free CashFlow per Share
- -2.24
- Capex to Operating CashFlow
- -0
- Capex to Revenue
- 0
- Capex to Depreciation
- 0.1
- Return on Invested Capital
- -0.64
- Return on Tangible Assets
- -0.4
- Days Sales Outstanding
- 74.77
- Days Payables Outstanding
- 352.58
- Days of Inventory on Hand
- 315.49
- Receivables Turnover
- 4.88
- Payables Turnover
- 1.04
- Inventory Turnover
- 1.16
- Capex per Share
- 0
Balance Sheet
- Cash per Share
- 6,57
- Book Value per Share
- 0,82
- Tangible Book Value per Share
- 0.82
- Shareholders Equity per Share
- 0.82
- Interest Debt per Share
- 3.19
- Debt to Equity
- 3.25
- Debt to Assets
- 0.35
- Net Debt to EBITDA
- 1.57
- Current Ratio
- 8.15
- Tangible Asset Value
- 0,03 Bil.
- Net Current Asset Value
- 0,03 Bil.
- Invested Capital
- 246575000
- Working Capital
- 0,24 Bil.
- Intangibles to Total Assets
- 0
- Average Receivables
- 0,02 Bil.
- Average Payables
- 0,01 Bil.
- Average Inventory
- 7342500
- Debt to Market Cap
- 0.18
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
UroGen Pharma Ltd. Profile
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
- CEO
- Ms. Elizabeth A. Barrett
- Employee
- 203
- Address
-
400 Alexander Park
Princeton, 08540
UroGen Pharma Ltd. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Jason Drew Smith General Counsel, Chief Compliance Officer & Corporate Secretary |
70 |
| 2 |
Dr. Marina Konorty Ph.D. Executive Vice President of Research & Development and Technical Operations |
70 |
| 3 |
Mr. Michael J. Louie M.D., M.P.H., M.Sc. Senior Vice President of Medical Affairs & Clinical Development |
70 |
| 4 |
Mr. James Ottinger R.ph. Executive Vice President of Regulatory Affairs & Quality |
70 |
| 5 |
Mr. Bryon Wornson Executive Vice President of Talent, Advocacy & Communications |
70 |
| 6 |
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. Chief Business Officer |
70 |
| 7 |
Ms. Elizabeth A. Barrett President, Chief Executive Officer & Director |
70 |
| 8 |
Dr. Mark P. Schoenberg M.D. Chief Medical Officer |
70 |
| 9 |
Mr. Dong Kim Chief Financial Officer |
70 |
| 10 |
Vincent I. Perrone Senior Director of Investor Relations |
70 |
UroGen Pharma Ltd. Competitors
